BAN

(redirected from mesalamine)
Also found in: Dictionary, Thesaurus, Medical, Legal, Encyclopedia, Wikipedia.

BAN

Ban

A subdivision of the Moldovan leu or Romanian leu. One ban is equal in value to 1/100 of one leu. Its plural is bani.

BAN

References in periodicals archive ?
The results of the present study indicate that the addition of curcumin to mesalamine therapy was effective for inducing clinical and endoscopic remission in patients with mild-to-moderate active ulcerative colitis that had failed to respond to mesalamine alone.
Recent guidelines from the European Crohn's and Colitis Organisation recommend budesonide as more effective than mesalamine for mildly active, localized ileocecal Crohn's disease, and also recommend that budesonide or systemic corticosteroids are preferable for treating moderately active localized ileocecal disease.
A 2007 systematic review found 1 RCT of the anti-inflammatory drug mesalamine (mesalazine, 5-aminosalicylic acid) for preventing diverticulitis.
The delivery system of many mesalamines is dependent upon a specific pH in order to release, but since the pH levels in the GI tract can vary, it could affect the proper release and efficacy of the medication.
Practice Implications: This interesting study completed in Japan suggests that 2 g/day of curcumin safely and effectively improves remission rates in patients with UC taking sulfasalazine or mesalamine compared to those taking the drugs alone.
This patient was treated with a proton pump inhibitor, a short course of prednisone, and a maintenance regimen that included azathioprine and mesalamine.
People in both groups also got pills containing the anti-inflammatory drug mesalamine.
Safe drugs: Mesalamine, sulfasalazine, topical 5-ASA, systemic corticosteroids, cephalosporins, ampicillin, and erythromycin.
Canasa is currently the only suppository form of mesalamine available in the United States.
PHILADELPHIA -- Treatment with either folic acid or mesalamine was linked to about a 90% reduction in the incidence of colorectal cancer in a case-control study including 48 patients with inflammatory bowel disease.
Design and Duration: Randomized, double-blind, placebo-controlled trial with a treatment period of six months followed by a six-month observation period during which patients continued on sulfasalazine or mesalamine.